Paroxetine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Paroxetine: From Unrecorded Original Indication to Ohdo Syndrome and Variants
One-Sentence Summary
Paroxetine is an SSRI-class antidepressant (per the evidence pack’s mechanistic notes), though its specific original approved indication and mechanism of action are not recorded in this evidence pack. The TxGNN model predicts a possible link to Ohdo Syndrome and Variants, a rare congenital malformation syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications — model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack (data gap) |
| Predicted New Indication | Ohdo Syndrome and Variants |
| TxGNN Prediction Score | 99.11% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Detailed mechanism of action data for paroxetine is not available in this evidence pack ([Data Gap]). Based on the information present, paroxetine is described as an SSRI-class antidepressant, acting primarily via inhibition of presynaptic serotonin reuptake (SERT inhibition).
Ohdo syndrome and its variants are a group of rare congenital multiple-malformation disorders caused by germline mutations in chromatin-modifying/transcriptional-regulation genes (e.g., KAT6B, KAT6A, MED12, DDX3X), which disrupt craniofacial and skeletal development during embryogenesis. There is no established pharmacological or mechanistic pathway connecting SSRI activity to these developmental gene pathways.
Given the absence of a plausible mechanistic link and the absence of any supporting clinical or literature evidence, this candidate should be treated as a high-scoring but mechanistically unsupported TxGNN association — potentially a false positive arising from graph-topology proximity rather than genuine biological relevance.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Drug Interactions: The evidence pack records 327 total documented interactions for paroxetine. Notable examples include:
| Interacting Drug | Severity |
|---|---|
| Bupropion | Major |
| Lorcaserin | Major |
| Diethylpropion | Major |
| Dolasetron | Major |
| Eliglustat | Major |
| Palonosetron | Major |
| Phentermine | Major |
| Morphine | Moderate |
| Acetylsalicylic acid | Moderate |
| Clarithromycin | Moderate |
| Cimetidine | Moderate |
| Chlorpropamide | Moderate |
| Glimepiride | Moderate |
| Repaglinide | Moderate |
| Dronabinol | Moderate |
| Eluxadoline | Moderate |
| Picosulfuric acid | Moderate |
| Polyethylene glycol (3350 w/ electrolytes) | Moderate |
| Sodium sulfate | Moderate |
| Aprepitant | Minor |
TFDA label warnings and contraindications are not currently available in this evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: A Blocking-severity data gap (TFDA label warnings/contraindications unavailable) prevents this candidate from clearing the S1 safety screening stage. Independently, the predicted indication itself has no supporting clinical trials or literature (L5 — prediction only) and no plausible mechanistic rationale connecting SSRI pharmacology to a chromatin-regulation congenital malformation syndrome. Paroxetine is also not currently marketed in Taiwan (0 registrations).
To proceed, the following is needed:
- TFDA product label (PDF) parsed for warnings/contraindications (DG001)
- DrugBank MOA data to properly assess mechanistic plausibility (DG002)
- Independent expert review of the mechanistic rationale before any further evidence collection is commissioned for this drug–indication pair
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.